Loading…
← CockpitCompetitor Analysis › 300181.SZ Zhejiang Jolly Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Zhejiang Jolly Pharmaceutical Co., Ltd. Class A300181.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Major

Zhejiang pharma maker known for a fungal-fermentation traditional medicine capsule used to treat insomnia and fatigue.

≈ A small, single-product Chinese sleep-aid drugmakerMomentum strong 68
Mkt cap
$1.34B
US dollars, full cap
Free float
82%
of shares outstanding
$/day
$21.4M
20-day average traded
Fwd P/E
13.0×
forward earnings
ROIC−WACC
+6.9 pp
WACC 6.9%
Hurdle
-19 pp
Req g minus delivered
Next earnings
155 days
22 Apr 2027
Close · CNYCN¥12.64
1D-1.6%
1W+2.5%
1M-4.1%
3M-15.2%
6M-14.7%
YTD-21.8%
1Y-26.4%
ATR %2.5%
52w lowhigh32.2% off high

What Zhejiang Jolly Pharmaceutical does

Zhejiang pharma maker known for a fungal-fermentation traditional medicine capsule used to treat insomnia and fatigue.

One capsule product carries most sales, sold mainly through hospital prescriptions and pharmacies, so reimbursement listing and prescriber habits matter more than the rest of the range.

In one line: A small, single-product Chinese sleep-aid drugmaker.

Products and services

  • Wuling Capsule (insomnia/fatigue TCM)
  • Other TCM and probiotic products

Customers

  • Hospitals
  • Retail pharmacies

Where it sits in the supply chain

  • Pharmaceuticals
  • Traditional Chinese medicine
  • Fungal-fermentation drugs

What could go right

  • Rising insomnia/stress treatment demand

What could go wrong

  • Single-product brand dependence
  • TCM efficacy scrutiny

Moat: narrow (brand, IP / patents). Patented fermentation process and an established brand in a niche TCM sleep-aid category.

Headquarters: Huzhou, Zhejiang, China · Employees: 2,861

Named competitors

Zhejiang Jolly Pharmaceutical at a glance

Size Zhejiang Jolly Pharmaceutical (300181.SZ) is a China Health Care company (Pharmaceuticals: Major) with a market value of $1.34B, the 1679th largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥12.64 on 18 Nov 2026.

Performance Over six months the shares fell 14.7%, against -17.3% for the median peer and -20.0% for the China market (cap-weighted) — 10th highest of 20 in its peer set.

Growth Revenue grew 16.6% over the last twelve months (peer median +9.2%); the operating margin is 19.7% (peer median -1.9%).

Valuation It trades at 13.0× forward earnings against a peer median of 20.4× (5th cheapest of 11).

Price implies For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -19 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 6.9 points above its cost of capital (6.9% WACC).

Next results Next results expected around 22 Apr 2027 (exchange calendar; dates can move).

Relative performance

809010021 May 202621 Aug 202618 Nov 2026300181.SZ 87Peer median 83
Six months, rebased to 100: Zhejiang Jolly Pharmaceutical against the median of its 20 peers (local-currency closes).

Zhejiang Jolly Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥3.27BCN¥3.02BCN¥2.56BCN¥1.93BCN¥1.79B
Revenue growth—+18%+33%+8%—
Gross profitCN¥2.06BCN¥1.83BCN¥1.52BCN¥1.29BCN¥1.24B
EBITDAn/aCN¥832MCN¥666MCN¥490MCN¥386M
Net incomeCN¥617MCN¥632MCN¥508MCN¥383MCN¥273M
Free cash flowCN¥203MCN¥128MCN¥34.8MCN¥157MCN¥143M
Capital expenditureCN¥170MCN¥287MCN¥263MCN¥132MCN¥178M
Total debtCN¥964MCN¥774MCN¥482MCN¥244MCN¥196M

Quarterly statements and history in the cockpit →

Zhejiang Jolly Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-20%0%+20%NANO226950002099068760688293MNKDINVAOCUL002020LBRX301263002332DMRAAMPHMARKSANS310210140410300204300181.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Zhejiang Jolly Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

0%+50%+100%0×200×400×688293MNKDINVA0020203012634516300204300181.SZRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Zhejiang Jolly Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%-20%0%20%068760688293INVA0020200023324516AMPHMARKSANS300181.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Zhejiang Jolly Pharmaceutical is the large dot.

Zhejiang Jolly Pharmaceutical competitors and peer comparison

Head to head with its named competitors (300181.SZ vs 002603.SZ vs 600535.SS)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Zhejiang Jolly Pharmaceutical 300181.SZ$1.34B-15%+17%20%13.0×3.9%
Shijiazhuang Yiling Pharmaceutical 002603.SZ$3.83B-7%+32%21%17.5×-3.9%
Tasly Pharmaceutical 600535.SS$3.19B-2%-4%19%16.7×-7.5%

How Zhejiang Jolly Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Zhejiang Jolly Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure300181.SZPeer medianRank in peer set
1-month return-4.1%-1.8%8th lowest of 20
6-month return-14.7%-17.3%10th highest of 20
Distance from 52-week high-32.2%-42.5%7th highest of 20
Revenue growth (TTM)+16.6%+9.2%6th highest of 18
Operating margin19.7%-1.9%3rd highest of 18
Forward P/E13.0×20.4×5th cheapest of 11
Growth the price implies (Req g, 7 yrs)3.9%1.1%4th most demanding of 9
Growth delivered (Del g)+22.8%+11.3%2nd highest of 9
Hurdle (Req g minus delivered)-18.9 pp-10.4 pp3rd least demanding of 9
ROIC minus cost of capital+6.9 pp-5.9 pp3rd highest of 18

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Zhejiang Jolly Pharmaceutical 300181.SZChina$1.34B-15%+17%20%13.0×3.9%+22.8%
Nanobiotix NANO.PAFrance$1.35B-32%-77%-392%n/an/an/a
OliX Pharmaceuticals 226950.KSSouth Korea$1.35B-51%+27%-384%n/an/an/a
Zhejiang Hisoar Pharmaceutical 002099.SZChina$1.33B-2%+9%-13%n/an/an/a
Celltrion Pharm 068760.KSSouth Korea$1.33B-23%+16%12%n/a10.2%+18.1%
Shanghai OPM Biosciences 688293.SSChina$1.32B+36%+133%11%48.6×25.9%+23.1%
Windward Bio WWBUnited States$1.31Bn/an/an/an/an/an/a
MannKind MNKDUnited States$1.31B+25%+32%-2%174.4×n/an/a
Innoviva INVAUnited States$1.31B-17%+12%38%9.5×-17.2%+3.9%
Ocular Therapeutix OCULUnited States$1.31B-26%-10%-681%n/an/an/a
Zhejiang Jingxin Pharmaceutical 002020.SZChina$1.39B-19%+1%19%12.1×-9.6%+4.6%
LB Pharmaceuticals LBRXUnited States$1.30B+43%n/an/an/an/an/a
Guangdong Taienkang Pharmaceutical 301263.SZChina$1.30B-24%+2%-2%60.7×n/an/a
Zhejiang Xianju Pharmaceutical 002332.SZChina$1.28B-1%+8%11%17.7×-0.4%-1.3%
Damora Therapeutics DMRAUnited States$1.42B-5%n/an/an/an/an/a
Nippon Shinyaku 4516.TJapan$1.42B-20%+18%18%7.9×-18.1%+7.0%
Amphastar Pharmaceuticals AMPHUnited States$1.27B+64%+3%19%9.1×2.5%+15.5%
Marksans Pharma MARKSANS.NSIndia$1.43B+36%+24%20%23.2×31.0%+16.6%
Voronoi 310210.KSSouth Korea$1.43B-62%-100%-438,152%n/an/an/a
Mezzion Pharma 140410.KSSouth Korea$1.43B-15%+13%-211%n/an/an/a
Staidson (Beijing) Biopharmaceuticals 300204.SZChina$1.26B-41%-24%-51%522.3×n/an/a

Questions

Who are Zhejiang Jolly Pharmaceutical's main competitors?
Named competitors: Yiling Pharmaceutical (002603.SZ), Tasly Pharmaceutical (600535.SS). The cockpit's measured peer set (industry) also includes Nanobiotix (NANO.PA), OliX Pharmaceuticals (226950.KS), Zhejiang Hisoar Pharmaceutical (002099.SZ), Celltrion Pharm (068760.KS), Shanghai OPM Biosciences (688293.SS), Windward Bio (WWB).
Is Zhejiang Jolly Pharmaceutical expensive compared with its peers?
On forward p/e it trades at 13.0× against a peer median of 20.4×, 5th cheapest of 11 in its peer set. For today's price to make sense, revenue must grow about 4% a year for seven years (Req g). Recent delivered growth is +23%, so the hurdle is -19 pp: the price already allows for a slowdown.
How has Zhejiang Jolly Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -14.7% against -17.3% for the median peer; over one year -26.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.